摘要
目的探讨肝细胞肝癌 (hepatocellularcarcinoma ,HCC)病人血清IL 12、IL 2、sIL 2R水平的相关关系。方法 6 0例HCC病人 ,随机分为 2组。试验组 (30例 )接受IL 2 (IL 2 10 0万U/d× 7d ,静脉点滴注射 )治疗 ;对照组 (30例 )没有接受生物治疗。两组基础治疗基本相似。采用酶联免疫吸附 (ELISA)法检测所有病人治疗前后血清IL 12、IL 2、sIL 2R水平变化。结果血清IL 12水平与血清IL 2水平正相关 ,IL 12与sIL 2R无关 ,IL 2与sIL 2R负相关。IL 2治疗后平均血清IL 12、IL 2、sIL 2R水平显著性升高。IL 2治疗后血清IL 12水平下降的HCC病人预后差。结论IL 12与IL 2之间可能存在一个反馈环路 ,sIL 2R是这个环路的负调节因素。IL 2治疗可刺激内源性IL 12释放。HCC病人的预后可能与IL 2诱生的IL
ObjectiveTo study the relationship among serum levels of interleukin-12 (IL-12), interleukin-2 (IL-2), and soluble interleukin-2 receptor (sIL-2R) in patients with hepatocellular carcinoma (HCC).Methods60 patients were randomized into two groups, group A (n=30) received IL-2 (1 MIU·day -1 for seven days), group B (n=30) served as control. Venous blood levels of IL-12?IL-2 and sIL-2R in all patients were measured by enzyme-linked immunosorbent assay (ELISA) before and after the IL-2 administration. Results There was positive correlation between serum levels of IL-2 and IL-12, negative correlation between serum levels of IL-2 and sIL-2R and no correlation between that of IL-12 and sIL-2R. Mean serum levels of IL-12,IL-2 and sIL-2R significantly (P<0.01) increased in response to IL-2 treatment. The decrease in IL-12 level in spite of IL-2 treatment predict a poor prognosis.Conclusion There is a feedback loop between IL-12 and IL-2,and sIL-2R may play as a negative regulator, exogenous IL-2 may stimulate the release of IL-12, and the IL-12 response to IL-2 may predict the prognosis of HCC patients.
出处
《中华普通外科杂志》
CSCD
北大核心
2002年第4期211-213,共3页
Chinese Journal of General Surgery
